Cardiovascular Inflammation Reduction Trial

Status: open

[433957-19] Cardiovascular Inflammation Reduction Trial (CIRT): A randomized, double-blind, placebo-controlled, event-driven trial of weekly low-dose methotrexate (LDM) in the prevention of cardiovascular events among stable coronary artery disease patients.

Treatment for Coronary Artery Disease

Contact Us Or call 251-471-7027


The Cardiovascular Inflammation Reduction Trial (CIRT) is a randomized clinical trial investigating whether taking low-dose methotrexate reduces heart attacks, strokes, or death in people with type 2 diabetes or metabolic syndrome that have had a heart attack or multiple coronary blockages. This trial is funded by the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH). IRB Number 13-082


This trial is sponsored by National Heart Lung and Blood Institute.

Providers Associated With This Trial

Principal Investigator

This link will open in a new tab or window.